View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Simen Mortensen
  • Simen Mortensen

Ncc (Buy, TP: SEK150.00) - Q1 in line with our expectations

Q1 is low season for NCC, but we believe the EBIT miss versus Infront consensus was likely due to some consensus participants overlooking the early Easter effect. With the Q1 results broadly in line with our estimates, we have made only minor forecast changes, and reiterate our BUY and SEK150 target price.

ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Markus Henriksson
  • Viktor Stenlöf
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

+450bp gross margin underpins turnaround

A strong start to 2024 with 5-13% divisional profit beats. +450bp gross margin expansion validates turnaround story. BUY on deep values and turnaround, TP DKK 235 (225).

Rune Majlund Dahl
  • Rune Majlund Dahl

GN Group (Buy, TP: DKK250.00) - Gaining confidence in management

The Q1 results beat our expectations and consensus, with c5% organic growth and a 12.5% EBITA margin, driven by the Hearing division, while Enterprise and Gaming & Consumer saw c0% organic revenue growth in still-muted markets. The 2024 guidance was maintained for organic sales growth of 2–8%, an EBITA margin of 12–14%, and FCF of >DKK700m. At the upcoming CMD, we expect focus to be on One-GN and market outlook. We reiterate our BUY, and have raised our target price to DKK250 (230).

Oliver Metzger
  • Oliver Metzger

GN Store Nord : Strong hearing aid business, stabilisation at Enterpri...

>Q1 review – Strong beat on bottom line - GN Store Nord achieved Q1 revenues of DKK 4,303m (+2.1% y-o-y, 0%/+1% vs ODDO BHF/consensus). Q1 adj. EBITA reached DKK 538m (+218% y-o-y, margin 12.5%), which was a strong beat by 35% of our estimates and by 32% vs consensus. EPS reached DKK 1.74 (vs DKK 0.87/0.85 expected). The 2024 guidance is confirmed.GN Hearing - Excellent organic growth on new Nexia platform - GN Hearing’s Q1 revenues of DKK 1,737m (+7....

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
 PRESS RELEASE

Interim Report Q1 2024: GN Store Nord delivered organic revenue growth...

Interim Report Q1 2024: GN Store Nord delivered organic revenue growth of 5% reaching an EBITA margin of 12.5% Highlights GN delivered continued execution across the three divisions resulting in 5% organic revenue growth for the GroupThe Hearing division delivered continued market share gains leading to 14% organic revenue growth, resulting in 8.2 percentage point increase in the divisional profit margin supported by synergies and a successful ReSound Nexia roll-outThe Enterprise division continued its relentless commercial execution in a stabilizing market leading to 0% organic revenue gr...

 PRESS RELEASE

Annual General Meeting 2024

Annual General Meeting 2024 COMPANY ANNOUNCEMENT NO 13/2024 - May 1, 2024  On Tuesday, 30 April 2024 at 4 pm CEST Royal Unibrew A/S held its Annual General Meeting at which the below resolutions were adopted. Agenda and full contents of the proposals: 1.      Report on the Company’s business activities during the yearThe Board of Directors’ report was noted. 2.      Presentation of the audited Annual Report for 2023 for approval The Company’s Annual Report for 2023 was adopted by the Annual General Meeting. 3.      Resolution to discharge the Board of Directors and the Execu...

ABB Ltd: 2 directors

Two Directors at ABB Ltd sold 62,402 shares at between 44.780CHF and 44.933CHF. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...

Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK400.00) - 2024 likely to be back-end loaded

We forecast Q1 organic revenue growth of 4.7% YOY (in line with consensus), driven by Hearing Care (we forecast 4.9%) and Diagnostics (we forecast 8.4%), while Hearing Aids faces a tough YOY comparable (we forecast 3.6%). We expect 2024 to be back-end loaded and driven by Oticon Intent. We expect maintained 2024 guidance of 4–8% organic growth, c1% M&A growth, c-1% FX, and EBIT of DKK4.6bn–5.0bn. We reiterate our BUY and DKK400 target price.

Martin Huseby Karlsen
  • Martin Huseby Karlsen

Aker Solutions (Hold, TP: NOK40.00) - Probably dead money for a while

Despite Q1 EBITDA 25% above consensus (but in line with our estimate) and 2024e EBITDA c10% higher on updated guidance, we struggle to get excited about the story. The investment case suffers from a lack of financial details for the OneSubsea JV, which we believe investors would need to support a higher valuation. Meanwhile, a forecast working capital unwind and weak cash transition would probably be in focus. We also sense growing concern about the 2026+ outlook as Norway projects end, and back...

ABGSC Construct. & Real Estate Research ... (+4)
  • ABGSC Construct. & Real Estate Research
  • Fredrik Stensved
  • Markus Henriksson
  • Viktor Stenlöf

Improving market - BUY the leader

EBIT down 4-1%. Uptick in sold units to continue in Q2'24e. Housing market rebound in the making - BUY

ABGSC Oil & Oil Services Research ... (+2)
  • ABGSC Oil & Oil Services Research
  • Haakon Amundsen

Stronger performance than expected

Revenue and margin beat in Q1, and '24 guidance up on good visibility. Dividends will come — BUY

Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Coor Service Management (Buy, TP: SEK59.00) - 2024 renewals already de...

Coor reported a solid Q1, in line with expectations, and we have only tweaked our forecasts following the results. A strong contract extension trend has derisked 2024, with contract volumes YTD already matching the full year 2023 delivery, suggesting a more stable base for growth and efficiency improvements. We continue to like its FCF profile, low operating risk, scope for value-enhancing acquisitions, and strong yield support. We reiterate our BUY and have raised our target price to SEK59 (57....

JM AB: 2 directors

Two Directors at JM AB bought/maiden bought 1,550 shares at between 183.170SEK and 184.000SEK. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

Rune Majlund Dahl
  • Rune Majlund Dahl

GN Group (Buy, TP: DKK230.00) - Time to rebuild credibility

We forecast Q1 organic sales growth of 3.0% YOY (consensus 2.8%) and an EBITA margin of 9.7% (consensus 9.6%). We see Hearing as starting well, and despite still-negative growth in Enterprise, we expect unchanged 2024 guidance. The upcoming CMD offers management scope to rebuild credibility, and we expect updated long-term targets to reflect “One-GN”. We reiterate our BUY and have raised our target price to DKK230 (215).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch